查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2026050

中重度類風濕性關節炎（RA）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

Moderate to Severe Rheumatoid Arthritis (RA) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 155 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 西班牙類風濕關節炎市場預計將從 7.7 億美元成長到 8.38 億美元，顯示市場將溫和擴張。
  • 受大規模的患者群體和生物製藥的高滲透率推動，德國類風濕性關節炎 (RA) 市場預計將從 31.53 億美元擴大到 35.54 億美元。
  • 推動市場成長的因素如下：
  • 生物製藥和JAK抑制劑的應用日益廣泛
  • 慢性病管理中治療療程的延長
  • 雖然患者數量的成長保持穩定到中等水平，但市場規模的成長是由高附加價值治療方法和聯合治療推動的。
  • 未來的成長取決於下一代標靶治療和疾病修正治療的改進策略。

中重度類風濕性關節炎(RA) 概述

中重度類風濕性關節炎（RA）是一種慢性全身性自體免疫疾病，其特徵是滑膜持續炎症，導致進行性性關節破壞、疼痛、僵硬、腫脹和不可逆的功能障礙。除關節受累外，該疾病也常引起心血管疾病、間質性肺病、骨質疏鬆症和慢性疲勞等全身性併發症，顯著增加發病率和死亡率風險。

在中重度階段，患者的日常生活活動和生活品質會顯著受損。疾病活動度評估採用綜合指標（如DAS28、CDAI），並輔以類風濕因子（RF）和抗環瓜氨酸肽（抗CCP）抗體等血清學標記。疾病進展是由複雜的免疫調節異常引起的，涉及促炎細胞激素，特別是TNF-α、IL-6和JAK-STAT訊號通路。

治療以目標導向（T2T）方法為核心，強調早期積極干預，以達到持續緩解或低疾病活動度。傳統的合成DMARDs，特別是胺基甲基葉酸，仍然是治療的基礎，並常與生物DMARDs（例如TNF抑製劑、IL-6受體拮抗劑）或靶向合成藥物（例如JAK抑製劑）聯合使用，用於療效不佳的患者。糖皮質激素和非類固醇抗發炎藥（NSAIDs）可作為輔助性治療，快速控制症狀，但不適用於長期緩解疾病。

儘管治療方法取得了顯著進展，但仍有相當一部分患者會出現原發性或繼發性治療失敗、疾病持續活動或治療不耐受，需要多次更換治療方案。此外，長期安全性問題、高昂的治療費用以及治療反應的個體差異仍然是實現最佳疾病管理的挑戰。

治療格局正日益聚焦於精準醫療，將基於生物標記的患者分層、新型免疫標靶和最佳化的治療順序策略相結合，以增強持續療效。未來的創新旨在解決難治性疾病，最大限度地減少全身性併發症，並最終實現持續緩解，同時提高安全性並改善以患者為中心的治療效果。

主要亮點

  • 在法國，類風濕性關節炎 (RA) 患者人數預計將從 309,511 人增加到 331,872 人，反映出疾病負擔的穩定上升。
  • 德國的病例數預計將從 1,046,761 例增加到 1,122,386 例，這持續表明存在大規模患者群體。
  • 中度至重度類風濕性關節炎 (RA) 仍會因進行性性關節損傷和全身性併發症而導致嚴重的身體殘疾。
  • 儘管有先進的生物製藥和標靶治療，但治療抗藥性和疾病復發仍然很常見。
  • 為了改善長期治療效果，個人化醫療和基於生物標記的治療方法正受到越來越多的關注。

格式化和更新訊息

  • 詳細報告（PDF）
  • 市場預測模型（基於微軟Excel）
  • 流行病學數據（MS Excel，互動式工具）
  • 高階主管洞察（PPT簡報）
  • 其他功能：定期更新、自訂和顧問支援。
  • 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

  • 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
  • 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
  • 未來十年市場收入和病患佔有率的預測是多少？
  • 哪些因素對市場趨勢影響最大？
  • 受訪專家對目前和新興的治療方法有何看法？
  • 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
  • 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
  • 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

大公司

  • Qilu Pharmaceutical Co., Ltd.
  • Toll Biotech Co. Ltd.（Beijing）
  • Beijing VDJBio Co., LTD.
  • Lifordi Immunotherapeutics, Inc.
  • AbbVie
  • Capstan Therapeutics
  • Celltrion
  • Eli Lilly and Company
  • Guangdong Hengrui Pharmaceutical Co., Ltd
  • Shanghai Longwood Biopharmaceuticals Co., Ltd.
  • Abivax SA
  • Hoffmann-La Roche

目錄

第1章：主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

  • 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

  • 重點
  • 發病率/盛行率
  • 已確診並接受藥物治療的患者人數
  • 合併症
  • 其他相關患者群

第4章 市場規模及預測

  • 重點
  • 市場促進因素與限制因素
  • 按藥物類別分類的趨勢
  • 各國具體趨勢

第5章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要治療方法概述及KOL洞察
  • 新興治療方法
  • 重點
  • 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
  • 值得關注的早期研發管線

第6章：未滿足的需求與目標產品分析

  • 主要未滿足的需求以及透過新興治療方法實現的未來可能性
  • TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

簡介目錄

Moderate to Severe Rheumatoid Arthritis Market Outlook

Thelansis's "Moderate to Severe Rheumatoid Arthritis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Moderate to Severe Rheumatoid Arthritis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Moderate to Severe Rheumatoid Arthritis Overview

Moderate to severe rheumatoid arthritis (RA) is a chronic, systemic autoimmune disorder characterized by persistent inflammation of the synovial membrane, leading to progressive joint destruction, pain, stiffness, swelling, and irreversible functional disability. The disease extends beyond joints, frequently manifesting with systemic complications such as cardiovascular disease, interstitial lung disease, osteoporosis, and chronic fatigue, significantly increasing morbidity and mortality risk.

At moderate to severe stages, patients experience substantial impairment in daily functioning and quality of life, with disease activity assessed using composite indices (e.g., DAS28, CDAI) and supported by serological biomarkers such as rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies. Disease progression is driven by complex immune dysregulation involving pro-inflammatory cytokines, particularly TNF-a, IL-6, and JAK-STAT signaling pathways.

Management is centered on a treat-to-target (T2T) approach, emphasizing early, aggressive intervention to achieve sustained remission or low disease activity. Conventional synthetic DMARDs, particularly methotrexate, remain the backbone of therapy and are frequently combined with biologic DMARDs (e.g., TNF inhibitors, IL-6 receptor antagonists) or targeted synthetic agents such as JAK inhibitors for patients with inadequate response. Corticosteroids and NSAIDs are used adjunctively for rapid symptom control but are not suitable for long-term disease modification.

Despite significant therapeutic advancements, a considerable proportion of patients exhibit primary or secondary treatment failure, persistent disease activity, or intolerance to therapies, necessitating multiple treatment switches. Additionally, long-term safety concerns, high treatment costs, and heterogeneity in treatment response continue to pose challenges in optimal disease management.

The evolving treatment landscape is increasingly focused on precision medicine, incorporating biomarker-driven patient stratification, novel immune targets, and optimized sequencing strategies to improve durability of response. Future innovation aims to address refractory disease, minimize systemic complications, and ultimately achieve sustained remission with improved safety and patient-centric outcomes..

Key Highlights

  • In France, prevalent RA cases are projected to increase from 309,511 to 331,872, reflecting a steady rise in disease burden.
  • In Germany, prevalence is expected to grow from 1,046,761 to 1,122,386, indicating a consistently large patient pool.
  • Moderate to severe RA continues to drive significant disability due to progressive joint damage and systemic complications.
  • Despite availability of advanced biologics and targeted therapies, treatment resistance and disease flares remain common.
  • Increasing focus on personalized medicine and biomarker-driven treatment selection to improve long-term outcomes.

Market Overview

  • The Spain RA market is projected to grow from $770M to $838M, reflecting moderate expansion.
  • The Germany RA market is expected to increase from $3,153M to $3,554M, driven by a large patient base and high biologic adoption.
  • Market growth is supported by:
  • Increased uptake of biologics and JAK inhibitors
  • Longer treatment duration in chronic disease management
  • Despite stable-to-moderate patient growth, market value is driven by premium therapies and combination treatment approaches.
  • Future growth will depend on next-generation targeted therapies and improved disease-modifying strategies.

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support
  • As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025-2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market's trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

  • Qilu Pharmaceutical Co., Ltd.
  • Toll Biotech Co. Ltd. (Beijing)
  • Beijing VDJBio Co., LTD.
  • Lifordi Immunotherapeutics, Inc.
  • AbbVie
  • Capstan Therapeutics
  • Celltrion
  • Eli Lilly and Company
  • Guangdong Hengrui Pharmaceutical Co., Ltd
  • Shanghai Longwood Biopharmaceuticals Co., Ltd.
  • Abivax S.A.
  • Hoffmann-La Roche

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)